stockrow
Friday 6 November 2026
Export PRAX’s income statement to Excel — free account
Praxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
276.58
13.99
+5.33%
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) P/E ratio
Praxis Precision Medicines, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| PRAX Praxis Precision Medicines, Inc. | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| RYTM Rhythm Pharmaceuticals, Inc. compare | n/m |
| KRYS Krystal Biotech, Inc. compare | 39.2× |
| CORT Corcept Therapeutics Incorporated compare | 47.5× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)